At a glance
ClinicalIndex Comparison RecordN/ACompleted· 130 enrolled
Drug / intervention
Acticor/Rivacor ICDs/CRT-Ds +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BIO|MASTER.Cor Family Study
In Brief
A clinical study evaluating Acticor/Rivacor ICDs/CRT-Ds and Plexa S DX for Heart Failure and Tachyarrhythmia. Completed, enrolled 130 participants across 13 sites in 7 countries.
Detailed Summary
Post-Market Clinical Follow-up of the new Cor Family ICDs/CRT-Ds (Acticor, Rivacor) and the new Plexa ProMRI S DX right ventricular lead to provide post-market data and supporting evidence for the clinical safety and performance of the devices.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure, Tachyarrhythmia
CountriesAustria, Germany, Hungary, Latvia, Netherlands, Slovakia, Switzerland
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedMar 2019
Enrollment StartApr 2019
Primary CompletionDec 2020
Study CompletionSep 2021
TodayJul 2026
First PostedMar 27, 2019
Enrollment StartApr 30, 2019
Primary CompletionDec 21, 2020
Study CompletionSep 24, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 7.3 years ago
Interventions
Acticor/Rivacor ICDs/CRT-Dsdevice
pre-defined device programming, measurements and follow-up schedule
Plexa S DXdevice
Implantation, measurements and follow-up schedule